Clin2
NCT07333651Possibly a fitNot yet recruiting

Radioactive seeds plus systemic therapy for oligoprogressive cancers

Oligometastatic Disease

Part of Cancer, Digestive system, Lungs & breathing clinical trials.

This trial tests a procedure that places tiny radioactive seeds directly into tumors that have started growing again in patients with lung or colorectal cancer that has spread. It combines this with standard drug therapy to see if it can better control the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
90 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have been diagnosed with non-small cell lung cancer or colorectal cancer that has spread to other parts of the body.
  • Your cancer must have progressed in up to 5 spots (lesions) while other spots remain stable, as shown on a CT or PET scan.
  • You must have received at least one prior standard treatment for your metastatic cancer.
  • The growing spots must be safely reachable for a procedure that implants tiny radioactive seeds, as determined by your doctors.
  • You must be well enough to undergo the procedure and ongoing therapy, with an ECOG performance status of 0, 1, or 2.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06918951Recruiting
Stereotactic radiation vs standard radiation for limited cancer spread

This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.

Surrey, British Columbia
NCT05223803Recruiting· Phase 2
Study radiation for early metastatic prostate cancer

This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.

La Jolla, California
NCT07333664Not yet recruiting· Phase 2
Radioactive seed implants plus standard therapy for multiple metastatic tumors

This trial tests a treatment that places tiny radioactive seeds directly into some of your tumors, combined with your usual cancer therapy. It is for people who have 6 to 10 tumors that have spread to other parts of the body (not the brain). The goal is to see if adding this implant procedure helps control the tumors better.

Jinan, Shandong
NCT07277777Not yet recruiting· Phase 2
Radioactive seeds plus immunotherapy for solid tumors

This trial tests whether placing tiny radioactive seeds directly into a tumor, combined with immunotherapy (a drug that helps your immune system attack cancer), can help treat cancers that are new, have come back, or have spread. It's for people who can safely have the seed procedure and are eligible for immunotherapy.

Jinan, Shandong
NCT07437625Not yet recruiting· Phase 2
Seed implants plus freezing for advanced cancer with many or large tumors

This trial tests a combination of two local treatments—radioactive seed implants and cryoablation (freezing)—for people with cancer that has spread to multiple sites or created large tumors that can't be surgically removed. The goal is to see if targeting up to five specific spots can control the disease and reduce symptoms.

Jinan, Shandong
NCT07171996Recruiting
Radioactive seed therapy for spinal tumors

This trial tests a procedure where tiny radioactive seeds are placed into spinal tumors to relieve pain and control growth. It is for people with cancer that has spread to the bone and who are able to undergo the procedure safely.

Jinan, Shandong

Hear when a new Oligometastatic Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.